Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Allogene Therapeutics Selects Selected Standard Fludarabine And Cyclophosphamide As Lymphodepletion Regimen To Be Used In ALPHA3 Study Evaluating Cemacabtagene Ansegedleucel In First-line Consolidation For Large B-Cell Lymphoma

Author: Benzinga Newsdesk | August 01, 2025 07:37am

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm
Unplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rate and Safety Profile
ALPHA3 Study Now Proceeds as a Two-Arm Randomized Study Comparing Cema-cel After Standard FC Lymphodepletion to Observation; Scheduled Futility Analysis Remains 1H 2026, as Planned
Conference Call and Webcast Scheduled for Today at 8:00 AM PT/11:00 AM ET

Posted In: ALLO